Free tool
FAERS Monitor: Balversa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212018 or its brand name (Balversa, Erdafitinib). Reports on generic versions are filed under their own applications.
Reports
1,247
Serious
919
74% of reports
Hospitalization
263
Death reported
349
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death272
- off label use104
- diarrhoea100
- stomatitis82
- onycholysis58
- fatigue53
- hyperphosphataemia53
- nail disorder53
- dry mouth46
- nail discolouration45
- dry eye43
- disease progression42
- mucosal inflammation38
- onychomadesis38
- decreased appetite37
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 79 |
| 2020 | 234 |
| 2021 | 193 |
| 2022 | 246 |
| 2023 | 142 |
| 2024 | 154 |
| 2025 | 106 |
| 2026 | 92 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,912 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| onycholysisSignal | 58 | 650.2 | 503.2 | 35,582 |
| hyperphosphataemiaSignal | 53 | 426.3 | 326.4 | 21,523 |
| nail discolourationSignal | 45 | 195.3 | 146.3 | 8,410 |
| onychomadesisSignal | 38 | 154.1 | 112.5 | 5,578 |
| nail disorderSignal | 53 | 102.8 | 78.9 | 5,212 |
| mucosal inflammationSignal | 38 | 24.5 | 17.9 | 834 |
| stomatitisSignal | 82 | 22.8 | 18.5 | 1,693 |
| dry eyeSignal | 43 | 14.5 | 10.8 | 530 |
| dry mouthSignal | 46 | 9.6 | 7.2 | 346 |
| disease progressionSignal | 42 | 6.0 | 4.4 | 170 |
| deathSignal | 272 | 5.3 | 4.8 | 992 |
| decreased appetiteSignal | 37 | 2.7 | 2.0 | 38 |
| diarrhoeaSignal | 100 | 2.6 | 2.2 | 101 |
| off label useSignal | 104 | 2.0 | 1.7 | 53 |
| fatigue | 53 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.